Disclaimer
The alfapump® system is currently not approved in the United States or Canada. In the United States and Canada, the alfapump® system is currently under clinical investigation (POSEIDON Study) and is being studied in adult patients with refractory or recurrent ascites due to cirrhosis. DSR® therapy is still in development and it should be noted that any statements regarding safety and efficacy arise from ongoing pre-clinical and clinical investigations which have yet to be completed. There is no link between the DSR® therapy and ongoing investigations with the alfapump® system in Europe, the United States or Canada.
Chief Executive Officer
“We have demonstrated that the alfapump® addresses the clear unmet patient needs in liver refractory ascites and malignant ascites, delivering a clinically effective and convenient therapy that improves patient quality of life.
Through our breakthrough and proprietary Direct Sodium Removal therapy, we are developing alfapump® DSR, a convenient and fully implanted system for the management of volume overload due to heart failure.
This IPO will provide the financing for the North American pivotal study on the alfapump® for liver refractory and recurrent ascites, the European commercial roll-out of the alfapump®, first-in-human DSR studies, other clinical programmes in Europe including a study on the alfapump® for malignant ascites, a registry for cirrhosis patients that have been implanted with the alfapump® and a study on the impact of albumin replacement therapy on clinical outcomes in alfapump® patients, the partial repayment of principal on an outstanding loan and other general corporate purposes.”
MARCH 18, 2019
Sequana Medical announces the end of the stabilisation period of its offering
MARCH 1, 2019
Mid-Stabilisation Period Announcement
FEBRUARY 20, 2019
Mid-Stabilisation Period Announcement
FEBRUARY 8, 2019
Sequana Medical raises €27.5 million in successful Initial Public Offering
FEBRUARY 7, 2019
Sequana Medical announces the Coverage of the Base Offering of Its Initial Public Offering on Euronext Brussels
JANUARY 31, 2019
Sequana Medical Launches Its Initial Public Offering on Euronext Brussels
JANUARY 29, 2019
Sequana Medical receives Breakthrough Device designation from the FDA for its alfapump®
NOVEMBER 30, 2018
Update regarding the Launch of an Initial Public Offering on Euronext Brussels
NOVEMBER 15, 2018
UK NICE recommends use of the alfapump® for the treatment of refractory ascites caused by cirrhosis under special arrangements
NOVEMBER 8, 2018
Sequana Medical Announces Intention to Launch an Initial Public Offering on Euronext Brussels
NOVEMBER 8, 2018
Sequana Medical Announces the Appointments of Industry Experts Pierre Chauvineau as Chairman and Wim Ottevaere as Non-Executive Director
Email: IR@sequanamedical.com
Tel: +32 498 053579
